A006280 Stock Overview
A biopharmaceutical company, develops and sells pharmaceutical drugs in South Korea and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 1/6 |
GC Biopharma Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩114,700.00 |
| 52 Week High | ₩131,100.00 |
| 52 Week Low | ₩93,000.00 |
| Beta | 1.09 |
| 1 Month Change | 0.35% |
| 3 Month Change | -2.71% |
| 1 Year Change | -9.83% |
| 3 Year Change | -64.60% |
| 5 Year Change | -4.42% |
| Change since IPO | -61.46% |
Recent News & Updates
Is GC Biopharma (KRX:006280) A Risky Investment?
May 25
GC Biopharma Corp.'s (KRX:006280) Business And Shares Still Trailing The Industry
Mar 08Recent updates
Is GC Biopharma (KRX:006280) A Risky Investment?
May 25GC Biopharma Corp.'s (KRX:006280) Business And Shares Still Trailing The Industry
Mar 08We Think Green Cross (KRX:006280) Can Stay On Top Of Its Debt
May 02Are Green Cross Corporation's (KRX:006280) Mixed Financials Driving The Negative Sentiment?
Mar 10Shareholders Are Thrilled That The Green Cross (KRX:006280) Share Price Increased 268%
Feb 18Green Cross (KRX:006280) Has A Somewhat Strained Balance Sheet
Jan 31Calculating The Intrinsic Value Of Green Cross Corporation (KRX:006280)
Jan 14What You Need To Know About Green Cross Corporation's (KRX:006280) Investor Composition
Dec 27
Green Cross Corporation's (KRX:006280) Financials Are Too Obscure To Link With Current Share Price Momentum: What's In Store For the Stock?
Dec 09Does Green Cross's (KRX:006280) Statutory Profit Adequately Reflect Its Underlying Profit?
Nov 21Shareholder Returns
| A006280 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | 2.6% | -2.7% | -3.1% |
| 1Y | -9.8% | -1.2% | 1.5% |
Return vs Industry: A006280 underperformed the KR Biotechs industry which returned -1.2% over the past year.
Return vs Market: A006280 underperformed the KR Market which returned 1.5% over the past year.
Price Volatility
| A006280 volatility | |
|---|---|
| A006280 Average Weekly Movement | 3.4% |
| Biotechs Industry Average Movement | 8.2% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in KR Market | 11.2% |
| 10% least volatile stocks in KR Market | 2.3% |
Stable Share Price: A006280 has not had significant price volatility in the past 3 months.
Volatility Over Time: A006280's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1967 | 2,098 | Il-Sup Huh | www.globalgreencross.com |
GC Biopharma Corp., a biopharmaceutical company, develops and sells pharmaceutical drugs in South Korea and internationally. It provides over-the-counter drugs, such as Acustop Cataplasma for Analgesic and anti-inflammatory effect; Kenhancer plaster for anti-inflammatory; and Zenol Cool Type and Zenol Mild Hot Type drugs to treat anti-inflammatory and pain relief. The company also offers Albumin-GCC injection (inj.) for hypoalbuminemia and shock in acute hemorrhage, as well as low synthesis of albumin; Antithrombin-III (AT-III) inj.
GC Biopharma Corp. Fundamentals Summary
| A006280 fundamental statistics | |
|---|---|
| Market cap | ₩1.31t |
| Earnings (TTM) | -₩29.49b |
| Revenue (TTM) | ₩1.63t |
0.8x
P/S Ratio-44.4x
P/E RatioIs A006280 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A006280 income statement (TTM) | |
|---|---|
| Revenue | ₩1.63t |
| Cost of Revenue | ₩1.16t |
| Gross Profit | ₩470.26b |
| Other Expenses | ₩499.76b |
| Earnings | -₩29.49b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.58k |
| Gross Margin | 28.78% |
| Net Profit Margin | -1.80% |
| Debt/Equity Ratio | 46.4% |
How did A006280 perform over the long term?
See historical performance and comparison